Ovagen Peptide 20mg

Description

What Is Ovagen Peptide?

Ovagen peptide is a synthetic tripeptide bioregulator with the amino acid sequence Glu-Asp-Leu (EDL), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Ovagen belongs to the Khavinson bioregulator peptides class — short regulatory peptides that exhibit tissue-specific gene expression modulation at physiological concentrations. Ovagen’s primary targets are hepatic (liver) tissue and gastrointestinal epithelium, where it has been studied for its capacity to normalize gene expression patterns associated with hepatocyte function, liver detoxification capacity, and GI mucosal barrier integrity in aging and stress models.

As a liver bioregulator, ovagen operates through the Khavinson epigenetic mechanism — direct interaction with complementary DNA sequences in promoter regions of liver-specific and GI-specific genes. This transcription-level modulation differentiates bioregulator peptides from conventional hepatoprotective compounds that act through antioxidant scavenging or metabolic pathway inhibition. PrymaLab Ovagen 20mg is manufactured to high purity standards and supplied exclusively for qualified preclinical research.

Ovagen 20mg: Key Specifications

How Ovagen Works: Bioregulator Mechanism of Action

Ovagen operates through the Khavinson model of peptide bioregulation, in which short peptides interact with specific DNA sequences in the promoter regions of target genes. For ovagen, these target gene clusters govern hepatocyte metabolic function, Phase I and Phase II detoxification enzyme expression, bile acid homeostasis, and gastrointestinal mucosal cell turnover and barrier integrity.

Hepatic Gene Expression Normalization

Research from the Khavinson group demonstrates that ovagen selectively modulates liver-specific gene expression, including genes encoding cytochrome P450 enzymes (CYP family), glutathione S-transferases, and albumin synthesis pathways. In aged liver tissue models, ovagen administration restored transcriptional profiles toward patterns characteristic of younger, metabolically active hepatocytes. This gene-level normalization mechanism distinguishes ovagen from conventional hepatoprotective compounds that primarily function as antioxidant scavengers (such as silymarin or N-acetylcysteine) without addressing the underlying transcriptional decline.

Gastrointestinal Mucosal Support

Beyond its hepatic effects, ovagen has been studied for modulation of GI mucosal barrier function. The gastrointestinal epithelium undergoes continuous renewal and is highly dependent on coordinated gene expression programs governing cell proliferation, differentiation, and tight junction protein expression. Preclinical data from the St. Petersburg Institute indicates that ovagen supports GI mucosal gene expression patterns associated with epithelial barrier integrity, mucin production, and inflammatory cytokine regulation in the intestinal epithelium.

Liver-Gut Axis Integration

Modern hepatology research recognizes the liver-gut axis as a critical bidirectional communication pathway where gut barrier integrity directly affects hepatic inflammation and liver function directly impacts intestinal health. Ovagen’s dual targeting of both hepatic and GI tissue positions it uniquely among the Khavinson bioregulator peptides for research into this integrated organ system, particularly in aging models where both hepatic detoxification capacity and GI barrier function decline simultaneously.

Ovagen Peptide Benefits: What Research Shows

The following reflects published preclinical and gerontological literature. PrymaLab Ovagen 20mg is supplied exclusively for research purposes.

Hepatic Detoxification and Metabolic Function

Published research from the Khavinson program reports that ovagen administration in aged animal models was associated with improved hepatic metabolic markers, including normalized cytochrome P450 enzyme activity, enhanced glutathione conjugation capacity, and improved albumin synthesis rates — all indicators of restored hepatocyte functional competence. These effects support the bioregulation hypothesis that short peptides can restore liver function that declines during biological aging.

Liver Tissue Repair and Anti-aging Effects

In gerontological models examining age-related hepatic decline, ovagen has been studied for its effects on hepatocyte proliferation capacity, liver tissue architecture maintenance, and resistance to oxidative stress-induced hepatocyte damage. Published data indicates that bioregulator peptide treatment helped maintain liver tissue function at ages where untreated controls showed significant structural and functional deterioration.

Gastrointestinal Barrier and Gut Health

Preclinical studies have examined ovagen’s effects on intestinal epithelial barrier markers, including tight junction protein expression (occludin, claudins, ZO-1), goblet cell mucin production, and inflammatory cytokine profiles in intestinal tissue. Research indicates improved GI barrier function parameters in ovagen-treated aged tissue models, supporting its application in research on age-related gut permeability and intestinal inflammation.

Ovagen vs. Livagen: Liver Bioregulator Comparison

How to Store and Handle PrymaLab Ovagen 20mg

1. Store lyophilized at −20°C. Keep the sealed vial desiccated and protected from light. Stable for 24+ months under these conditions.
2. Allow vial to reach room temperature before opening to prevent condensation.
3. Reconstitute with appropriate sterile solvent. Use bacteriostatic water or sterile saline added slowly along the vial wall.
4. Use reconstituted solution within 2–4 weeks. Store at 2–8°C and mark reconstitution date.
5. Avoid repeated freeze-thaw cycles. Aliquot into single-use portions if needed.
6. Retain the Certificate of Analysis for lot traceability and research documentation.

Why Choose PrymaLab Ovagen 20mg?

PrymaLab supplies Ovagen 20mg as a high-purity research-grade bioregulator peptide verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch ships with a unique lot number and Certificate of Analysis. Independent third-party analytical testing ensures unbiased results and full traceability for GLP-compliant research environments.

Frequently Asked Questions About Ovagen Peptide

What is ovagen peptide and what does it target?

Ovagen is a synthetic tripeptide bioregulator (Glu-Asp-Leu, EDL) developed by Professor Vladimir Khavinson that targets liver tissue (hepatocytes) and gastrointestinal epithelium. It belongs to the Khavinson bioregulator peptide class and has been studied for its capacity to modulate hepatic and GI gene expression patterns associated with detoxification capacity, metabolic function, and mucosal barrier integrity in aging research models.

What are the reported ovagen peptide benefits?

Published research reports that ovagen peptide benefits include normalization of hepatic detoxification enzyme expression (cytochrome P450 family, glutathione S-transferases), improved albumin synthesis in aged liver models, restored gastrointestinal barrier integrity markers, and modulation of inflammatory cytokines in intestinal tissue. All benefits are from preclinical and gerontological research settings.

How does ovagen differ from livagen?

Both target hepatic tissue, but ovagen (EDL) is a dual-organ bioregulator targeting both liver and gastrointestinal epithelium, making it relevant to liver-gut axis research. Livagen (KEDA) is more specifically focused on liver tissue gene regulation and has demonstrated unique chromatin decondensation activity in hepatocyte models. Researchers often study both peptides together for comprehensive hepatic support protocols.

How is ovagen stored and reconstituted?

Store lyophilized ovagen at −20°C, desiccated and protected from light. After reconstitution with sterile solvent, store at 2–8°C and use within 2–4 weeks. Avoid repeated freeze-thaw cycles. The lyophilized form is stable for 24+ months under proper storage conditions.

Is ovagen approved for human use?

No. PrymaLab Ovagen 20mg is a research compound intended exclusively for preclinical research. It has not been approved by the FDA or any regulatory authority for human therapeutic use. Researchers are responsible for compliance with all applicable institutional and regulatory requirements.

Research Disclaimer

For Research Use Only. PrymaLab Ovagen 20mg is intended exclusively for qualified preclinical research use by trained laboratory professionals. This product is not intended for human consumption, therapeutic use, veterinary treatment, or any application outside controlled research environments. Ovagen has not been approved by the FDA or any equivalent regulatory authority for therapeutic use. All research applications described are drawn from published preclinical and gerontological literature. Researchers are solely responsible for regulatory compliance.